SEPTIN9 and neoplasm: To test this hypothesis, we conducted a Next-Generation Sequencing (NGS) analysis and measured the methylation status of multiple CpG-rich subregions in the Septin9 promoter from CRC tumor tissues, compared with their paired adjacent normal tissues.